Stock comparison
Halozyme Therapeutics
Teleflex
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HALO
Halozyme Therapeutics
Market cap
$8.41B
Sector
Healthcare
TFX
Teleflex
Market cap
$5.74B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HALO | TFX | Winner |
|---|---|---|---|
| Warren Buffett | 69B | 24F | HALO |
| Benjamin Graham | 73B | 26F | HALO |
| Philip Fisher | 55C | 23F | HALO |
| Peter Lynch | 43D | 1F | HALO |
| Joel Greenblatt | 30F | 27F | HALO |
| Charlie Munger | 70B | 18F | HALO |
| Terry Smith | 74B | 15F | HALO |
Side-by-side metrics
| Metric | HALO | TFX |
|---|---|---|
| Market cap | $8.41B | $5.74B |
| P/E (TTM) | 24.0x | - |
| EV/EBIT | 10.2x | 21.9x |
| ROIC (TTM) | 23.65% | 2.73% |
| Gross margin | 81.24% | 53.27% |
| Net margin | 23.13% | -35.89% |
| Revenue CAGR 5y | 33.23% | -8.23% |
| EPS CAGR 5y | -1.98% | - |
| Debt / Equity | 1.0x | 0.1x |
| Dividend yield | 0.0% | 1.05% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HALO leads on
- Net margin23.13%vs -35.89%+164%
- Revenue CAGR 5y33.23%vs -8.23%+125%
- ROIC (TTM)23.65%vs 2.73%+88%
- EV/EBIT10.2xvs 21.9x+54%
TFX leads on
- P/E (TTM)-vs 24.0x+124%
- Dividend yield1.05%vs 0.0%+100%
- Debt / Equity0.1xvs 1.0x+94%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.